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INTRODUCTION
About 40% of systemic cancer patients have one or more 
brain metastases [1]. Surgical resection, whole brain radio-
therapy (WBRT), radiosurgery, and chemotherapy are modal-
ities of brain metastasis treatment, and treatment decision is 
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Background    Up to 15% of all patients with brain metastases have no clearly detected primary site 
despite intensive evaluation, and this incidence has decreased with the use of improved imaging tech-
nology. Radiosurgery has been evaluated as one of the treatment modality for patients with limited brain 
metastases. In this study, we evaluated the effectiveness of radiosurgery for brain metastases from un-
known primary tumors.
Methods    We retrospectively evaluated 540 patients who underwent gamma knife radiosurgery 
(GKRS) for brain metastases radiologically diagnosed between August 1992 and September 2007 in our 
institution. First, the brain metastases were grouped into metachronous, synchronous, and precocious 
presentations according to the timing of diagnosis of the brain metastases. Then, synchronous and pre-
cocious brain metastases were further grouped into 1) unknown primary; 2) delayed known primary; and 
3) synchronous metastases according to the timing of diagnosis of the primary origin. We analyzed the 
survival time and time to new brain metastasis in each group.
Results    Of the 540 patients, 29 (5.4%) presented precocious or synchronous metastases (34 
GKRS procedures for 174 lesions). The primary tumor was not found even after intensive and repeated 
systemic evaluation in 10 patients (unknown primary, 34.5%); found after 8 months in 3 patients (delayed 
known primary, 1.2%); and diagnosed at the same time as the brain metastases in 16 patients (syn-
chronous metastasis, 55.2%). No statistically significant differences in survival time and time to new 
brain metastasis were found among the three groups.
Conclusion    Identification of a primary tumor before GKRS did not affect the patient outcomes. If 
other possible differential diagnoses were completely excluded, early GKRS can be an effective treat-
ment option for brain metastases from unknown primary tumor.
Key Words  Neoplasm metastasis; Neoplasms, Unknown primary; Radiosurgery.
made based on patient age, performance status, systemic dis-
ease status, brain metastasis status, and so on. For the treatment 
of limited brain metastases, radiosurgery has become the stan-
dard of treatment and could defer WBRT as late as possible to 
avoid neurocognitive dysfunction [2-6].
Up to 15% of all patients with brain metastases have no 
clearly detected primary site despite intensive evaluation, even 
though the incidence is decreasing owing to improved imaging 
technology. However, the outcome of patients with brain me-
tastases of unknown primary origin is still controversial [7-11].
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The aim of this study was to compare the effectiveness of 
gamma knife radiosurgery (GKRS) for brain metastases of un-
known primary origin according to the timing of diagnosis of 
the primary tumor.
MATERIALS AND METHODS
Patients’ characteristics
We performed GKRS for 540 patients with brain metastases 
from August 1992 to September 2007 in our institution. The 
study was approved by the Institutional Review Board of our 
institution (IRB No.: 4-2016-0734), as specified in the Declara-
tion of Helsinki. Of the 540 patients, 29 (5.4%) presented with 
precocious or synchronous metastases (34 GKRS procedures 
for 174 lesions). The primary tumor was not found even after 
intensive and repeated systemic evaluation in 10 patients (un-
known primary, 34.5%), was disclosed after 8 months in 3 pa-
tients (delayed known primary, 10.3%), and diagnosed up to 2 
months before the diagnosis of the brain metastases in 16 pa-
tients (synchronous metastasis, 55.2%). Of the 29 patients, 17 
were men and 12 were women. The mean age of the patients 
at the time of GKRS was 57.7 (range, 40–79) years. The medi-
an follow up duration was 16.0 (range, 1–35) months. The 
clinical, radiological, and radiosurgical data were retrospec-
tively reviewed (Table 1).
Radiosurgical procedures
GKRS was performed by using Leksell Gamma Knife Type 
C or Perfexion (Elekta Instrument AB, Stockholm, Sweden) 
under local anesthesia. Preoperative T1-weighted magnetic 
resonance images (MRI) with gadobutrol (Gd, Gadovist; Bay-
er Schering Pharma AG, Leverkusen, Germany) were used for 
dose planning. The images were transferred to a GammaPlan 
treatment system, and the treating neurosurgeon determined 
the target volume and identified the critical structures. Treat-
ment plans were constructed with single or multiple shots by 
using several sizes of collimators in order to construct a three-
dimensional plan that conformed to each target. The mean 
(SD) tumor margin dose was 17.6 (3.9) Gy.
Statistical analysis
The Statistical Package for the Social Sciences version 20.0.0 
(IBM, Armonk, NY, USA) was used. We analyzed survival 
time and time to new brain metastasis, and compared each 
among the 3 groups. Data were analyzed by using the Kaplan-
Meier survival analysis and log-rank (Mantel-Cox) test. A p 
value of <0.05 was considered statistically significant.
RESULTS
Clinical follow-up data were available for 29 patients. Ini-
tially, brain metastases were radiologically diagnosed by ex-
perienced neuroradiologists in most cases. We performed brain 
biopsy in 7 patients. There were 6 brain lesions in average on 
a MRI (Table 1). 
The estimated median survival time in each group was 27.1 
months in the unknown primary group, 35.3 months in the 
delayed known primary group, and 25.2 months in the syn-
chronous metastasis group. The difference in survival time 
among the groups was not statistically significant (Fig. 1).
The median times to new lesion detection after GKRS in 
each group were as follows: 4.6 months in the unknown pri-
mary group, 12.1 months in the delayed known primary 
Table 1. Clinical characteristics of patients
Characteristics No. of patients (%)
Age at diagnosis of brain 
  metastasis; median (year, range)
57.7 (40–79)
Gender
Male 17 (58.6)
Female 12 (41.4)
Number of brain lesions; mean (range) 6.0 (1–37)
Follow up duration; median 
  (months, range)
16.0 (1–35)
Final primary origin
Lung 12 (41.4)
Breast 2 (6.9)
Other (liver, stomach, ovary, thyroid, 
  and heart)
5
Unknown 10 (34.5)
Unknown
Synch Delayed
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Fig. 1. Kaplan-Meier curve of survival time showing no statistical-
ly significant difference in median survival time after gamma knife 
radiosurgery among the groups (p>0.05). Cum survival, cumula-
tive survival; Survival time, survival time in months; Unknown, un-
known primary group; Delayed, delayed known primary group; 
Synch, synchronous metastasis group.
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group, and 10.4 months in the synchronous metastasis group 
(p>0.05) (Fig. 2).
Of the 19 patients in the delayed known primary and syn-
chronous metastasis group, the most common site of the pri-
mary cancer was the lung in 12 patients, followed by the breast 
in 2 patients. The other sites were the liver, stomach, ovary, thy-
roid, and heart (Table 1). Diagnosis of the primary tumor could 
be confirmed by using brain biopsy in 3 patients and the pri-
mary site in 11 patients. Brain biopsy was performed in 7 pa-
tients, but the diagnosis of the primary tumor was possible in 
only 3 patients (42.9%). Leptomeningeal seeding occurred in 
one patient who got brain biopsy as a complication of biopsy.
Nineteen patients died during the follow-up period. Among 
these patients, 15 (78.9%) died of systemic cause; 3 (15.8%), 
of brain metastasis progression; and 1, of intracerebral hem-
orrhage not related to brain metastasis.
DISCUSSION
Over the last two decades, radiosurgery has become an al-
ternative treatment modality for brain metastases. Many au-
thors reported the efficacy of radiosurgery in comparison with 
that of surgical resection alone, WBRT alone, or combination 
therapies. Currently, radiosurgery is the treatment of choice 
for limited brain metastases to defer unnecessary WBRT in 
terms of neurocognitive dysfunction, repeated brain metasta-
ses, and so on [1-6].
Brain metastases are divided into metachronous, synchro-
nous, and precocious presentations according to the timing 
of the brain metastasis. Metachronous metastasis is defined 
as brain metastasis occurring >2 months after the diagnosis 
of the primary cancer; synchronous metastasis, as brain me-
tastasis occurring within 2 months of the diagnosis of the pri-
mary cancer; and precocious metastases, as brain metastasis 
diagnosed before the primary cancer is found. Synchronous 
and precocious brain metastases are often grouped together 
for evaluation. Up to 15% of all patients with brain metastases 
have no clearly detected primary cancer even after intensive 
and repeated systemic evaluations. The incidence of brain me-
tastases of unknown primary origin is decreasing owing to 
the improvements of imaging technology. However, only a few 
studies have reported results about the outcome of patients 
with unknown primary brain metastases, and the results are 
discrepant [7-11].
Le Chevalier et al. [8] reported 120 consecutive cases of 
patients who presented with brain metastases as the primary 
sign of malignancy. In 58 patients, the primary site remained 
unknown. However, survival was almost identical between 
the patients with known and unknown primary sites. They 
concluded that extensive evaluations to identify primary sites 
do not appear to be rational in patients presenting with brain 
metastases. Nguyen et al. [9] also reported that the overall sur-
vival of patients whose primary tumors were known was sim-
ilar to that of patients in whom the primary tumor remained 
unknown. D’Ambrosio and Agazzi [10] reported that if a pa-
tient presents with brain metastases, overall prognosis is not 
affected by previous knowledge of a primary tumor and that 
whether the primary tumor was eventually found did not af-
fect survival rates. They treated metastatic brain tumors with 
resection followed by WBRT, GKRS with WBRT, WBRT alone, 
or steroid alone. In our study, we compared survival time and 
time to new brain metastases between the unknown primary, 
delayed known primary, and synchronous metastasis groups 
that were treated with GKRS only. Our results showed no 
statistically significant differences, which might be caused by 
the modest progression of the primary cancers.
Agazzi et al. [12] reported that the lung was the most fre-
quent primary site with significantly higher relative frequen-
cy in patients with initially unknown primary sites than in 
patients with known primary sites. Our data showed similar 
results, and in 12 of 19 patients, the primary cancer whose di-
agnosis was delayed was located in the lung. This might be due 
to the characteristic of lung cancer in aspects of limitation of 
chest radiography and computed tomography. In our series, 
one patient was finally diagnosed as having brain metastases 
from a rare cardiac myxoma.
Primary cancer origin and the efficacy of GKRS are contro-
versial. Gerosa et al. [13] reported that the results of treatment 
with GKRS alone were better than those with WBRT and are 
comparable with the results of the best-selected surgery-radia-
Fig. 2. Kaplan-Meier curve of the time to new brain metastases 
showing no statistically significant difference in median time to 
new brain metastases among the group (p>0.05). Cum survival, 
cumulative survival; Survival time, survival time in months; Un-
known, unknown primary group; Delayed, delayed known primary 
group; Synch, synchronous metastases group.
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tion series, even for oncotypes unresponsive to therapeutic ra-
diation, cystic tumors, and brain stem tumors. However, Black 
et al. [14] suggested that primary histology affected local fail-
ure rates in case of comparing breast cancer, lung cancer, and 
melanoma. According to our results, the origin of brain metas-
tases did not influence patient survival time and disease pro-
gression. In addition, GKRS alone for primary unknown brain 
metastases was an effective and successful treatment modality.
Multiple brain enhancing lesions do not always mean met-
astatic brain tumors, even in patients who have a systemic ca-
ncer history. Many other possibilities include lymphomas, mu-
ltifocal or multicentric high-grade gliomas, infectious diseases 
such as tuberculoma, demyelinating diseases, and vasculitis. 
Therefore, accurate diagnosis of multiple brain lesions is es-
sential before making the treatment decision for brain lesions. 
When the primary cancer is not diagnosed radiologically or 
pathologically, we could consider biopsy for brain lesions. 
However, even after brain biopsy, the diagnosis of metastatic 
brain tumors could be made, but the estimation of primary ca-
ncer is not usually easy, except for several pathologically dis-
tinct tumors such as choriocarcinoma, melanoma, renal cell 
carcinoma, and advanced gastric cancer. Moreover, biopsy-
related complications could occur, such as hemorrhage, infec-
tion, or leptomeningeal spread [15-17]. Hence, we should de-
cide to perform brain biopsy in selective cases and diagnose 
by using mostly radiological and clinical examinations.
We conclude that GKRS is an effective treatment modality 
even for brain metastases from unknown primary tumors. 
Identification of a primary tumor before GKRS did not affect 
the patients’ outcome. If other possible differential diagnoses 
were completely excluded, delaying the optimal treatment of 
brain metastases by evaluating the primary origin may not be 
appropriate.
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